Breast cancer research and treatment

publication venue for

Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. 2016
Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. 2014
BRCA1 R71K missense mutation contributes to cancer predisposition by increasing alternative transcript levels. 2011
Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature. 2007
Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer. 2002
History of infertility and risk of breast cancer: a prospective cohort study.. 199. 2023
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.. 197. 2022
Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study.. 197. 2022
Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer.. 194. 2022
Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.. 192. 2022
The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.. 192. 2022
A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.. 191. 2021
Dietary supplement use and documentation in a breast cancer survivorship clinic.. 191. 2021
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China.. 190. 2021
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.. 189. 2021
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).. 189. 2021
A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.. 188. 2021
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer.. 187. 2021
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic.. 188. 2021
Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry.. 186. 2021
Association of mammographic density measures and breast cancer "intrinsic" molecular subtypes.. 187. 2021
Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.. 186. 2020
Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer.. 186. 2020
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer.. 185. 2020
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.. 184. 2020
Hormone replacement therapy and mammographic density: a systematic literature review.. 182. 2020
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.. 181. 2020
LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.. 181. 2020
Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.. 179. 2019
The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.. 179. 2019
Mammographic screening in male patients at high risk for breast cancer: is it worth it?. 177. 2019
Dietary intake from birth through adolescence in relation to risk of benign breast disease in young women.. 177. 2019
Employment trends in young women following a breast cancer diagnosis.. 177. 2019
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.. 177. 2019
Elevated serum levels of sialyl Lewis X (sLe^X) and inflammatory mediators in patients with breast cancer.. 176. 2019
Does every woman presenting with malignant calcifications require a post lumpectomy mammogram?. 176. 2019
Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.. 176. 2019
Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.. 175. 2019
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.. 175. 2019
Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.. 175. 2019
Differences between screen-detected and interval breast cancers among BRCA mutation carriers.. 175. 2019
Comparison of treatment of early-stage breast cancer among Nurses' Health Study participants and other Medicare beneficiaries.. 174. 2019
Pre-diagnostic sex hormone levels and survival among breast cancer patients.. 174. 2019
Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.. 174. 2018
Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.. 173. 2018
Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.. 172. 2018
Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer.. 172. 2018
Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.. 172. 2018
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.. 171. 2018
Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient-provider interactions.. 170. 2018
Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.. 170. 2018
Associations of coffee consumption and caffeine intake with mammographic breast density.. 169. 2018
Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.. 168. 2017
The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study.. 167. 2017
Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.. 167. 2017
Alcohol consumption across the life course and mammographic density in premenopausal women.. 167. 2017
Increased risk of arterial thromboembolism in older men with breast cancer.. 166. 2017
Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study.. 166. 2017
Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.. 166. 2017
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.. 166. 2017
Breast cancer risk prediction: an update to the Rosner-Colditz breast cancer incidence model.. 166. 2017
Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.. 165. 2017
Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes.. 165. 2017
Extensions of the Rosner-Colditz breast cancer prediction model to include older women and type-specific predicted risk.. 165. 2017
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.. 165. 2017
Sexual health needs and educational intervention preferences for women with cancer.. 165. 2017
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.. 164. 2017
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.. 163. 2017
Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.. 163. 2017
Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.. 162. 2017
Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.. 162. 2017
Body size from birth through adolescence in relation to risk of benign breast disease in young women.. 162. 2017
Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa.. 162. 2016
Recurrence risk perception and quality of life following treatment of breast cancer.. 161. 2016
Estimating the OncotypeDX score: validation of an inexpensive estimation tool.. 161. 2016
Trends in cardiac mortality in women with ductal carcinoma in situ.. 161. 2016
The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer.. 161. 2016
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.. 161. 2016
Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.. 161. 2016
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.. 160. 2016
A prospective study of endometriosis and risk of benign breast disease.. 159. 2016
Understanding racial differences in health-related quality of life in a population-based cohort of breast cancer survivors.. 159. 2016
Breast cancer risk prediction using a clinical risk model and polygenic risk score.. 159. 2016
Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.. 159. 2016
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.. 158. 2016
Reproductive factors related to childbearing and mammographic breast density.. 158. 2016
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.. 158. 2016
Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians.. 158. 2016
Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia.. 157. 2016
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.. 157. 2016
Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.. 157. 2016
Healthy dietary patterns and risk of breast cancer by molecular subtype.. 155. 2016
Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium.. 155. 2016
Adolescent intake of animal fat and red meat in relation to premenopausal mammographic density.. 155. 2016
Prenatal factors and infant feeding in relation to risk of benign breast disease in young women.. 154. 2015
Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.. 154. 2015
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.. 154. 2015
Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.. 154. 2015
The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.. 153. 2015
Heat shock factor 1 induces cancer stem cell phenotype in breast cancer cell lines.. 153. 2015
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).. 151. 2015
Premenopausal plasma carotenoids, fluorescent oxidation products, and subsequent breast cancer risk in the nurses' health studies.. 151. 2015
Antihypertensive medication use and incident breast cancer in women.. 150. 2015
Mammographic breast density and breast cancer risk: interactions of percent density, absolute dense, and non-dense areas with breast cancer risk factors.. 150. 2015
Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study.. 149. 2015
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.. 149. 2015
Premenopausal plasma 25-hydroxyvitamin D, mammographic density, and risk of breast cancer.. 149. 2014
Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses' Health Studies.. 149. 2014
Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy.. 148. 2014
Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study.. 147. 2014
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.. 147. 2014
Ghrelin and des-acyl ghrelin inhibit aromatase expression and activity in human adipose stromal cells: suppression of cAMP as a possible mechanism.. 147. 2014
Adolescent physical activity and inactivity: a prospective study of risk of benign breast disease in young women.. 146. 2014
Differential impact of non-insulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus on breast reconstruction outcomes.. 146. 2014
Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival.. 146. 2014
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.. 146. 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.. 146. 2014
Dietary fat intake in relation to lethal breast cancer in two large prospective cohort studies.. 146. 2014
Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families.. 145. 2014
Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes.. 145. 2014
Adolescent physical activity in relation to breast cancer risk.. 145. 2014
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103.. 144. 2014
Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.. 143. 2014
Is there a role for routine screening MRI in women with LCIS?. 142. 2013
Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40?. 142. 2013
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.. 141. 2013
Vegetable protein and vegetable fat intakes in pre-adolescent and adolescent girls, and risk for benign breast disease in young women.. 141. 2013
Early predictors of not returning to work in low-income breast cancer survivors: a 5-year longitudinal study.. 140. 2013
Inflammatory breast cancer (IBC): clues for targeted therapies.. 140. 2013
Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis.. 139. 2013
Radial scars and subsequent breast cancer risk: results from the Nurses' Health Studies.. 139. 2013
Age-related longitudinal changes in depressive symptoms following breast cancer diagnosis and treatment.. 139. 2013
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.. 139. 2013
Genomic and expression analysis of microdissected inflammatory breast cancer.. 138. 2013
The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study.. 138. 2013
Body size throughout the life course and mammographic density in Mexican women.. 138. 2013
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.. 138. 2013
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. 138. 2013
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.. 137. 2012
Time to diagnosis and breast cancer stage by race/ethnicity.. 136. 2012
Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses' Health Studies.. 136. 2012
Explaining age-related differences in depression following breast cancer diagnosis and treatment.. 136. 2012
Urinary estrogens and estrogen metabolites and mammographic density in premenopausal women.. 136. 2012
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers.. 136. 2012
Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.. 135. 2012
Adolescent intakes of vitamin D and calcium and incidence of proliferative benign breast disease.. 134. 2012
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.. 134. 2012
Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation.. 135. 2012
Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression.. 135. 2012
Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification.. 135. 2012
Atypical ezrin localization as a marker of locally advanced breast cancer.. 134. 2012
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.. 133. 2012
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.. 132. 2012
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.. 132. 2011
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.. 132. 2011
Cadherin-catenin complex dissociation in lobular neoplasia of the breast.. 132. 2011
Improving communication of breast cancer recurrence risk.. 133. 2011
Use of high technology imaging for surveillance of early stage breast cancer.. 131. 2011
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.. 131. 2011
Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women.. 131. 2011
Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer.. 131. 2011
A SEER-Medicare population-based study of lymphedema-related claims incidence following breast cancer in men.. 130. 2011
COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin.. 130. 2011
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.. 129. 2011
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.. 129. 2011
The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.. 131. 2011
Characterizing the impact of 25 years of DCIS treatment.. 129. 2011
The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.. 129. 2011
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.. 132. 2011
A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women.. 126. 2011
Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer.. 128. 2011
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.. 125. 2010
Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women.. 127. 2010
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.. 124. 2010
A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.. 125. 2010
Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.. 126. 2010
Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study.. 123. 2010
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.. 123. 2010
Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase.. 123. 2010
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.. 123. 2010
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.. 123. 2010
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.. 119. 2010
A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.. 120. 2009
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.. 123. 2009
The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study.. 123. 2009
More radiotherapy for radiation-induced second malignancies?. 124. 2009
Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation.. 122. 2009
A prospective study of variability in mammographic density during the menstrual cycle.. 121. 2009
The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer.. 118. 2009
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.. 118. 2009
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.. 115. 2008
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.. 117. 2008
Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer.. 117. 2008
The impact of sharing results of a randomized breast cancer clinical trial with study participants.. 115. 2008
Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.. 115. 2008
Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.. 114. 2008
A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk.. 113. 2008
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer.. 113. 2008
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).. 113. 2008
Characterisation of aromatase expression in the human adipocyte cell line SGBS.. 112. 2008
alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.. 111. 2007
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.. 111. 2007
Influence of preoperative MRI on the surgical management of patients with operable breast cancer.. 111. 2007
Cognitive function in breast cancer patients prior to adjuvant treatment.. 110. 2007
Measures of energy balance and mammographic density in the Nurses' Health Study.. 109. 2007
Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer.. 107. 2007
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.. 105. 2007
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.. 100. 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.. 99. 2006
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.. 98. 2006
Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.. 95. 2005
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.. 92. 2005
Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.. 92. 2005
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles.. 91. 2005
Economic outcomes of breast cancer survivorship: CALGB study 79804.. 91. 2005
A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.. 90. 2005
Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer.. 82. 2003
Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer.. 77. 2003
The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer.. 75. 2002
The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.. 73. 2002
Role of transforming growth factor beta in the growth inhibition of human breast cancer cells by basic fibroblast growth factor.. 70. 2001
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.. 66. 2001
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.. 65. 2001
Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy.. 59. 2000
Overexpression of basic fibroblast growth factor (FGF-2) downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells.. 56. 1999
Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor.. 55. 1999
Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience.. 54. 1999
ErbB-2 protein in sera and tumors of breast cancer patients.. 49. 1998
Variation in endometrial thickening in women with amenorrhea on tamoxifen.. 48. 1998
p53Val135 temperature sensitive mutant suppresses growth of human breast cancer cells.. 30. 1994
Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies?. 13. 1989
Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin.. 9. 1987
Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.. 156. 2016
Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. 2010
Applicability of the Gail model for breast cancer risk assessment in Turkish female population and evaluation of breastfeeding as a risk factor. 2009
Obesity's impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer. 2017
Breast fat and breast cancer. 2012
First international TNBC conference meeting report. 2018
Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002. 2003
The WISDOM study: a new approach to screening can and should be tested.. 189. 2021
Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound. 2020
Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. 2018
Male breast cancer: a disease distinct from female breast cancer. 2018
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. 2018
Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). 2018
Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis. 2017
To be young, Black, and living with breast cancer: a systematic review of health-related quality of life in young Black breast cancer survivors. 2016
Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis. 2014
Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. 2013
Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research. 2013
Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. 2012
Impact of mammographic screening on the detection of good and poor prognosis breast cancers. 2011
Outcome of axillary staging in early breast cancer: a meta-analysis. 2010
Analysis of dermatologic events in patients with cancer treated with lapatinib. 2008
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. 2007
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. 2007
Is cognitive dysfunction a complication of adjuvant chemotherapy in the older patient with breast cancer? 2007
HER2 codon 655 polymorphism and breast cancer: results from kin-cohort and case-control analyses. 2005
Clinical management of women with genomic BRCA1 and BRCA2 mutations. 2001
Farnesyltransferase inhibitors and anti-Ras therapy. 1996
When can stereotactic core biopsy replace excisional biopsy?--A clinical perspective. 1995
Identification and management of the woman at increased risk for breast cancer development. 1994
Insulin-like growth factors in human breast cancer. 1991

VIVO Weill Cornell Medical College

Breast cancer research and treatment Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)